Importance Preventing relapse for adults with acute myeloid leukemia (AML) in first
remission is the most common indication for allogeneic hematopoietic cell transplant. The …

The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) for acute
myeloid leukemia (AML) relies on the graft-versus-leukemia (GVL)-effect. Relapse after allo …

Background: Measurable residual disease (MRD) test positivity during and after treatment in
patients with acute myeloid leukemia (AML) has been associated with higher rates of …

Simple Summary FLT3-ITD monitoring is essential in AML management, and there is a great
need for sensitive monitoring methods. We present a simple and easily applicable ITD …

Patient-and leukemia-specific factors assessed at diagnosis classify patients with acute
myeloid leukemia (AML) in risk categories that are prognostic for outcome. The induction …

Measurable residual disease (MRD) has been widely recognized as a biomarker for deeply
evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions …

The most common indication for allogeneic hematopoietic cell transplant (alloHCT) is
maintenance of remission after initial treatment for patients with acute myeloid leukemia …

In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent
sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell …

Relapse remains the most critical obstacle in treatment by allogeneic hematopoietic stem
cell transplantation (HSCT). Non-relapse mortality has improved annually, but relapse …

The ability to detect low level disease is key to our understanding of clonal heterogeneity in
acute myeloid leukemia (AML) and residual disease that elude conventional assays and …